Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glenmark grants generic Zetia rights to Par

Executive Summary

Par Pharmaceutical Inc., the generics division of specialty pharma company Par Pharmaceutical Cos. Inc. has received from Glenmark Generics Inc. USA exclusive US rights to sell 10mg tablets of ezetimibe, the generic of Merck & Co. Inc.'s cholesterol lowering product Zetia.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies